Shire Sues IMPAX Over ANDA for Adderall Generic

Law360, New York (December 30, 2003, 12:00 AM EST) -- Shire Laboratories Inc., a subsidiary of Shire Pharmaceuticals Group, filed a lawsuit in the U.S. District Court for the District of Delaware against IMPAX Laboratories over IMPAX’ plans to make a generic version of Shire’s Adderall drug for attention deficit hyperactivity disorder (ADHD) in children.

The lawsuit results from an abbreviated new drug application (ANDA) filed by IMPAX for a generic version of 30 mg Adderall XR. In the filing, IMPAX provided notice that it would seek to market its generic product before the expiration of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.